Rich pipelines and reasonable gradients... Domestic innovative giant pharmaceutical companies are concerned

In recent years, under the background of policies that vigorously promote innovative research and development, China's pharmaceutical innovation has entered a golden development period
.
The industry recommends focusing on domestic innovation giants with strong R&D capabilities, abundant pipelines, reasonable gradients, and outstanding product advantages, such as Hengrui Pharmaceuticals and Fosun Pharmaceuticals
.
It is understood that the policy encourages innovation, and many pharmaceutical companies invest in research and development to increase year by year
.
Statistics show that the R&D expenses of eight pharmaceutical companies including Hengrui Pharmaceuticals and Fosun Pharmaceuticals exceeded 1 billion yuan in the first three quarters
.
Among them, the research and development expenses of Hengrui Pharmaceuticals in the first three quarters increased by nearly 24% year-on-year, reaching 4.
142 billion yuan
.
Fosun Pharma's research and development expenses increased by nearly 29% year-on-year, reaching 2.
414 billion yuan
.
Take Hengrui Medicine as an example.
In recent years, the company has continued to increase its investment in innovative drugs.
After years of development, it has formed a large-scale and professional innovative drug R&D team with more than 4,500 people
.
According to the data in the semi-annual report, the company has obtained 5 production approvals for innovative drug preparations, 9 production approvals for generic drug preparations, and 41 drug clinical approvals
.
Obtained the consistency evaluation approval documents for 10 varieties, and completed the consistency evaluation application work of 2 products
.
Fosun Pharma has also maintained a high investment in research and development for a long time.
The company stated that it hopes to increase the sales revenue of innovative products to more than 30% in the next few years.
The long-term goal is more than 50%.
It will continue to promote innovation and transformation, strengthen research and development, The integration of supply chain, production and commercialization systems has promoted the improvement of business quality and operational efficiency, and achieved steady growth in performance
.
In addition, according to data from its semi-annual report, Fosun Pharma has nearly 2,600 R&D personnel; there are 240 projects under development for innovative drugs, generic drugs, biosimilar drugs, and consistency evaluation of generic drugs, including 72 innovative drugs
.
In recent years, China's pharmaceutical companies have been enthusiastic about innovation
.
According to the research report of Huachuang Securities, in the first three quarters of 2021, the number of domestic new drugs approved for the first time reached 18, and the number of approvals for the whole year of 2020 is 11, and the number of domestic new drugs approved has increased significantly. .
From the perspective of R&D investment, in addition to the aforementioned Hengrui Pharmaceuticals and Fosun Pharma, the growth rate of R&D expenses of many companies has increased significantly
.
For example, 33 pharmaceutical companies, such as Guofa, Dashenlin, and Guangzheng Ophthalmology, experienced a year-on-year growth rate of over 100% in R&D expenses in the first three quarters
.
Among them, Guofa shares grew by approximately 22272% year-on-year
.
The year-on-year growth rates of Dashenlin and Guangzheng Ophthalmology both exceeded 800%
.
Now entering the fourth quarter, 2021 national medical insurance negotiations will also start soon.
It is reported that innovative drugs such as PD-1 have attracted much attention
.
It is reported that this negotiation involves many companies such as Hengrui Pharmaceuticals, BeiGene, Rongchang Biological; in terms of drug types, new therapies such as double antibodies, ADCs, and CAR-T are expected to participate
.
For example, Rongchang Bio’s core product tetaxel (RC18) is used for the treatment of systemic lupus erythematosus, and vedicitumumab (RC48) is used for the treatment of gastric cancer.
They were qualified in China in March 2021 and June 2021, respectively.
Approval of listing
.
The company stated that it is actively preparing relevant materials for participating in medical insurance negotiations and expects to quickly expand product sales channels in a short period of time
.
Analysts said that under the promotion of national policies, China's pharmaceutical industry is constantly innovating and developing, and achieving both quality and quantity improvements
.
As data shows, during the five years from 2016 to 2020, China has launched 200 innovative drug products, focusing on the disease areas with the largest disease burden and the highest growth rate in China, and targeting the unmet clinical needs of Chinese patients, including tumors, digestive tract and Significant achievements in chronic diseases such as metabolism, respiration, and cardiovascular and cerebrovascular diseases
.
In the future, we look forward to the birth of more innovative drugs to benefit patients
.